Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Medtronic
Chubb
UBS
Colorcon
Novartis
Farmers Insurance
Citi
Harvard Business School
Federal Trade Commission

Generated: August 17, 2017

DrugPatentWatch Database Preview

Dial Company Profile

« Back to Dashboard

What is the competitive landscape for DIAL, and when can generic versions of DIAL drugs launch?

DIAL has two approved drugs.

There are two US patents protecting DIAL drugs.

There are four patent family members on DIAL drugs in four countries.

Summary for Applicant: Dial

Patents:2
Tradenames:3
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dial
DIAL
hexachlorophene
SOLUTION;TOPICAL017421-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Dialysis Sups
NORMOCARB HF 25
magnesium chloride; sodium bicarbonate; sodium chloride
SOLUTION;INJECTION021910-001Jul 26, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Dialysis Sups
NORMOCARB HF 35
magnesium chloride; sodium bicarbonate; sodium chloride
SOLUTION;INJECTION021910-002Jul 26, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Dialysis Sups
NORMOCARB HF 25
magnesium chloride; sodium bicarbonate; sodium chloride
SOLUTION;INJECTION021910-001Jul 26, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expirations for DIAL

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

International Patent Family for Dial Drugs

Country Document Number Estimated Expiration
Australia2620902► Subscribe
European Patent Office1347795► Subscribe
Canada2365787► Subscribe
World Intellectual Property Organization (WIPO)0249693► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Dial Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0483Netherlands► SubscribePRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYDRAAT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
00517Netherlands► SubscribePRODUCT NAME: ACETYLSALICYLZUUR EN ESOMEPRAZOLMAGNESIUMTRIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 107516 20110912; FIRST REGISTRATION: 540235954023675402375 2011120812
00482Netherlands► SubscribePRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105
00615Netherlands► SubscribePRODUCT NAME: NATRIUMSULFAAT, MAGNESIUMSULFAAT EN KALIUMSULFAAT; NAT. REGISTRATION NO/DATE: RVG 110863 20130417; FIRST REGISTRATION: BE 434323 20130220
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Daiichi Sankyo
McKesson
Deloitte
Mallinckrodt
Federal Trade Commission
Fish and Richardson
Johnson and Johnson
Citi
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot